

In the Claims

1-10. (canceled)

11. (currently amended) A method for reducing serum alanine aminotransferase (ALT) in a subject with hepatitis comprising the administration of an effective amount of a CC-chemokine mutant comprising SEQ ID NO: 1 and having reduced glycosaminoglycan (GAG)-binding activity to a subject with hepatitis~~patient, wherein the CC-chemokine mutant is a triple 40's CCL5/RANTES (Regulated upon Activation, Normal T-cell Expressed and Presumably Secreted) mutant.~~

12-19. (canceled)

20. (currently amended) The method according to claim 11, wherein the CC-chemokine mutant further comprises an immunoglobulin constant region.

21. (canceled)

22. (previously presented) The method according to claim 11, wherein the hepatitis is an autoimmune hepatitis.

23 (currently amended). The method according to claim 11, further comprising the measurement of serum ALT levels in said ~~patient~~subject.

24. (currently amended) A method for reducing serum alanine aminotransferase (ALT) levels in a patient comprising measuring serum ALT levels in the patient and administering an effective amount of a CC-chemokine mutant comprising SEQ ID NO: 1 and having reduced glycosaminoglycan (GAG)-binding activity to a patient, ~~wherein the CC-chemokine mutant is a~~

~~triple 40's CCL5/RANTES (Regulated upon Activation, Normal T-cell Expressed and Presumably Secreted) mutant.~~

25. (canceled)

26. (currently amended)      The method according to claim 24, wherein the CC-chemokine mutant further comprises an immunoglobulin constant region.